IDEAS home Printed from https://ideas.repec.org/a/spr/eujhec/v17y2016i8d10.1007_s10198-016-0808-z.html
   My bibliography  Save this article

Reimbursable drug classes and ceilings in Italy: why not only one?

Author

Listed:
  • Livio Garattini

    (IRCCS Institute for Pharmacological Research ‘Mario Negri’)

  • Alessandro Curto

    (IRCCS Institute for Pharmacological Research ‘Mario Negri’)

  • Anna Padula

    (IRCCS Institute for Pharmacological Research ‘Mario Negri’)

Abstract

No abstract is available for this item.

Suggested Citation

  • Livio Garattini & Alessandro Curto & Anna Padula, 2016. "Reimbursable drug classes and ceilings in Italy: why not only one?," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 17(8), pages 923-926, November.
    • Handle: RePEc:spr:eujhec:v:17:y:2016:i:8:d:10.1007_s10198-016-0808-z
    DOI: 10.1007/s10198-016-0808-z
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s10198-016-0808-z
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.
    File URL: https://libkey.io/10.1007/s10198-016-0808-z?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Garattini, Livio & Motterlini, Nicola & Cornago, Dante, 2008. "Prices and distribution margins of in-patent drugs in pharmacy: A comparison in seven European countries," Health Policy, Elsevier, vol. 85(3), pages 305-313, March.
    2. Garattini, Livio & van de Vooren, Katelijne & Curto, Alessandro, 2012. "Regional HTA in Italy: Promising or confusing?," Health Policy, Elsevier, vol. 108(2), pages 203-206.
    3. Livio Garattini & Alessandro Curto & Nick Freemantle, 2016. "Pharmaceutical Price Schemes in Europe: Time for a ‘Continental’ One?," PharmacoEconomics, Springer, vol. 34(5), pages 423-426, May.
    4. Livio Garattini & Simone Ghislandi, 2006. "Off-patent drugs in Italy," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 7(1), pages 79-83, March.
    5. Livio Garattini & Alessandro Curto & Katelijne Vooren, 2015. "Italian risk-sharing agreements on drugs: are they worthwhile?," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 16(1), pages 1-3, January.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Livio Garattini & Anna Padula & Nicholas Freemantle, 2021. "Do European pharmacists really have to trespass on medicine?," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 22(1), pages 1-4, February.
    2. Livio Garattini & Anna Padula, 2018. "Pharmaceutical pricing conundrum: time to get rid of it?," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 19(8), pages 1035-1038, November.
    3. Lucia Leporatti & Rosella Levaggi & Marcello Montefiori, 2021. "Beyond price: the effects of non-financial barriers on access to drugs and health outcomes," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 22(4), pages 519-529, June.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Wettstein, Dominik J. & Boes, Stefan, 2022. "How value-based policy interventions influence price negotiations for new medicines: An experimental approach and initial evidence," Health Policy, Elsevier, vol. 126(2), pages 112-121.
    2. Garattini, Livio & van de Vooren, Katelijne & Curto, Alessandro, 2015. "Cost-effectiveness of trastuzumab in metastatic breast cancer: Mainly a matter of price in the EU?," Health Policy, Elsevier, vol. 119(2), pages 212-216.
    3. Joan Costa-i-Font & Alistair McGuire & Nebibe Varol, 2011. "Does Pharmaceutical Price Regulation Affect the Adoption of Generic Competition? Evidence from the OECD, 1999-2008," CESifo Working Paper Series 3441, CESifo.
    4. Serra-Sastre, Victoria & Bianchi, Simona & Mestre-Ferrandiz, Jorge & O’Neill, Phill, 2021. "Does NICE influence the adoption and uptake of generics in the UK?," LSE Research Online Documents on Economics 113639, London School of Economics and Political Science, LSE Library.
    5. Magda Wladysiuk & Aleksander Araszkiewicz & Brian Godman & Katarzyna Szabert & Corrado Barbui & Alan Haycox, 2011. "Influence of patient co-payments on atypical antipsychotic choice in Poland," Applied Health Economics and Health Policy, Springer, vol. 9(2), pages 101-110, March.
    6. Livio Garattini & Anna Padula, 2018. "Patient empowerment in Europe: is no further research needed?," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 19(5), pages 637-640, June.
    7. Simone Ghislandi & Patrizio Armeni & Claudio Jommi, 2013. "The impact of generic reference pricing in Italy, a decade on," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 14(6), pages 959-969, December.
    8. Milena Vainieri & Francesca Ferrè & Stefania Manetti, 2021. "An Integrated Framework to Measure the Performance of Inter-Organizational Programme on Health Technology Assessment," Sustainability, MDPI, vol. 13(7), pages 1-17, March.
    9. Mareike Heimeshoff & Helge Hollmeyer & Jonas Schreyögg & Oliver Tiemann & Doris Staab, 2012. "Cost of Illness of Cystic Fibrosis in Germany," PharmacoEconomics, Springer, vol. 30(9), pages 763-777, September.
    10. Livio Garattini & Anna Padula, 2020. "HTA for pharmaceuticals in Europe: will the mountain deliver a mouse?," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 21(1), pages 1-5, February.
    11. Livio Garattini & Dante Cornago, 2006. "Pharmaceutical policy in Italy," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 7(2), pages 89-90, June.
    12. Chiara Bonassi & Fabio Pammolli & Massimo Riccaboni & Nicola Carmine Salerno, 2007. "Regolazione, innovazione e ciclo di vita dei prodotti - per una riforma del pricing al lancio e della governance della spesa nella farmaceutica pubblica," Working Papers CERM 02-2007, Competitività, Regole, Mercati (CERM).
    13. Ville Aalto-Setälä, 2008. "The impact of generic substitution on price competition in Finland," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 9(2), pages 185-191, May.
    14. Chiara Bonassi & Laura Magazzini & Fabio Pammolli & Massimo Riccaboni & Nicola Carmine Salerno, 2007. "Il prezzo di riferimento nel quadro regolatorio del mercato farmaceutico," Working Papers CERM 04-2007, Competitività, Regole, Mercati (CERM).
    15. Victoria Serra-Sastre & Simona Bianchi & Jorge Mestre-Ferrandiz & Phill O’Neill, 2021. "Does NICE influence the adoption and uptake of generics in the UK?," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 22(2), pages 229-242, March.
    16. Livio Garattini & Anna Padula & Nicholas Freemantle, 2021. "Pricing vaccines and drugs in Europe: worth differentiating?," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 22(9), pages 1345-1348, December.
    17. Stadhouders, Niek & Kruse, Florien & Tanke, Marit & Koolman, Xander & Jeurissen, Patrick, 2019. "Effective healthcare cost-containment policies: A systematic review," Health Policy, Elsevier, vol. 123(1), pages 71-79.
    18. Livio Garattini & Anna Padula, 2018. "Pharmaceutical pricing conundrum: time to get rid of it?," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 19(8), pages 1035-1038, November.
    19. Patricia M. Danzon & Michael F. Furukawa, 2011. "Cross-National Evidence on Generic Pharmaceuticals: Pharmacy vs. Physician-Driven Markets," NBER Working Papers 17226, National Bureau of Economic Research, Inc.
    20. Livio Garattini & Anna Padula, 2018. "Competition in pharmaceuticals: more product- than price-oriented?," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 19(1), pages 1-4, January.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:eujhec:v:17:y:2016:i:8:d:10.1007_s10198-016-0808-z. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.